Hemophilia



Hemophilia Mobile App Usability Pilot


Condition:   Hemophilia
Intervention:   Device: SureSource Engage application
Sponsors:   Healthcare Innovation Technology Lab;   Bayer
Active, not recruiting


Bleeding Risk Evaluation in Haemophilia Patients Under Antiplatelet Therapies


Condition:   Hemophilia
Intervention:   Other: Non interventional study
Sponsor:   Nantes University Hospital
Recruiting


PF-06741086 Multiple Dose Study in Severe Hemophilia


Condition:   Hemophilia A or B
Intervention:   Biological: PF-06741086
Sponsor:   Pfizer
Recruiting


Long-Term Safety, Tolerability, and Efficacy of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B


Condition:   Hemophilia B
Intervention:  
Sponsor:   Dimension Therapeutics
Recruiting


Drug Use Investigation of Kovaltry in Hemophilia A Patients


Condition:   Hemophilia A
Intervention:   Drug: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973)
Sponsor:   Bayer
Recruiting


National Survey of People With Haemophilia in Portugal


Condition:   Haemophilia
Intervention:  
Sponsors:   University of Minho;   Hospital Sao Joao;   Portuguese hemophilia association and other congenital coagulopathies
Completed


A Clinical Trial to Evaluate Prophylactic Emicizumab Versus no Prophylaxis in Hemophilia A Participants Without Inhibitors


Condition:   Hemophilia A
Intervention:   Drug: Emicizumab
Sponsors:   Hoffmann-La Roche;   Chugai Pharmaceutical
Active, not recruiting


Educational Physiotherapy in Haemophilia


Condition:   Haemophilia
Intervention:   Other: Educational physiotherapy group
Sponsor:   Real Fundación Victoria Eugenia
Completed


The Hemophilia Ultrasound Project


Conditions:   Hemophilia A;   Hemophilia B
Interventions:   Other: Ankle and Knee Ultrasound Joint Assessment;   Other: Ankle and Knee Magnetic Resonance Imaging
Sponsors:   University of Miami;   Shire
Recruiting


Evaluation of a Simple Pharmacokinetic Tool (myPKFiT™) to Guide Personalized Factor VIII Dosing in Patients With Hemophilia


Condition:   Hemophilia A
Intervention:  
Sponsors:   Victor Blanchette;   St. Paul's Hospital;   Montreal Children's Hospital of the MUHC;   Queen's University;   University Hospital, Motol;   University Hospital Brno;   Royal Children's Hospital;   Sydney Children's Hospitals Network;   Royal Prince Alfred Hospital, Sydney, Australia
Enrolling by invitation


Safety and Dose Finding Study of DTX101 (AAVrh10FIX) in Adults With Moderate/Severe to Severe Hemophilia B


Condition:   Hemophilia B
Intervention:   Genetic: AAVrh10FIX
Sponsor:   Dimension Therapeutics
Completed


Extension at 10 Years of the: "Observational Study Evaluating Efficacy and Costs of Secondary Prophylaxis vs On-demand Therapy With Kogenate Bayer in Patients With Severe Haemophilia A."


Condition:   Hemophilia A
Intervention:   Drug: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
Sponsor:   Bayer
Active, not recruiting


National Study of a Pharmacokinetic-Focused Educational Package for Patients With Severe Haemophilia A


Condition:   Hemophilia A
Intervention:   Behavioral: Educational Package
Sponsor:   Hampshire Hospitals NHS Foundation Trust
Active, not recruiting


Global Haemostatic Methods Following Administration of Bypassing Agents to Patients With Haemophilia With Inhibitors


Condition:   Hemophilia
Intervention:  
Sponsor:   Karolinska Institutet
Recruiting


Trial of AAV5-hFIX in Severe or Moderately Severe Hemophilia B


Condition:   Hemophilia B
Intervention:   Genetic: AAV5-hFIX
Sponsors:   UniQure Biopharma B.V.;   Chiesi Farmaceutici S.p.A.
Active, not recruiting


Platelet Function in Patients With Hemophilia A


Condition:   Hemophilia A
Intervention:  
Sponsors:   Boston Children’s Hospital;   Baxter Healthcare Corporation
Enrolling by invitation


Multicentre, Non-controlled, Prospective, Post-Marketing Safety Study Following Long-Term Prophylactic OptivateTreatment in Subjects With Severe Haemophilia A


Condition:   Haemophilia A
Intervention:   Biological: Optivate 500IU
Sponsor:   Bio Products Laboratory
Terminated


A Trial Investigating Safety and Efficacy of Treatment With BAY94-9027 in Severe Hemophilia A


Condition:   Hemophilia A
Intervention:   Biological: BAY94-9027
Sponsor:   Bayer
Active, not recruiting


Inhibitor Development in Patients With Hemophilia A Undergoing Surgery


Condition:   Hemophilia A
Intervention:  
Sponsors:   Emory University;   National Institutes of Health (NIH);   National Heart, Lung, and Blood Institute (NHLBI)
Completed


A Trial to Compare Prophylaxis Therapy to On-demand Therapy With a New Full Length Recombinant FVIII in Patients With Severe Hemophilia A


Condition:   Hemophilia A
Interventions:   Biological: rFVIII (BAY81-8973) on demand;   Biological: rFVIII (BAY81-8973) prophylaxis low-dose;   Biological: rFVIII (BAY81-8973) prophylaxis high-dose
Sponsor:   Bayer
Completed


Study of Biostate® in Children With Hemophilia A


Condition:   Hemophilia A
Intervention:   Biological: Biostate
Sponsors:   CSL Behring;   Parexel
Completed


First-in-Human and Proof-of-Mechanism Study of ARC19499 Administered to Hemophilia Patients


Condition:   Hemophilia
Interventions:   Drug: placebo control;   Drug: ARC19499
Sponsor:   Baxalta now part of Shire
Terminated


Study Evaluating Safety And Efficacy Of Moroctocog Alfa (AF-CC) In Previously Treated Hemophilia A Patients


Condition:   Hemophilia A
Interventions:   Biological: Moroctocog alfa ( AF-CC);   Procedure: Laboratory tests
Sponsor:   Pfizer
Completed


Phase I/IIa Study of FIXFc in Hemophilia B Patients


Condition:   Hemophilia B
Intervention:   Drug: rFIXFc
Sponsors:   Bioverativ Therapeutics Inc.;   Syntonix Pharmaceuticals, Inc.;   Swedish Orphan Biovitrum
Completed


Phase 3/4 Study of a Recombinant Protein-Free Factor VIII (rAHF-PFM): Comparison of Continuous Infusion Versus Intermittent Bolus Infusion in Hemophilia A Subjects Undergoing Major Orthopedic Surgery


Condition:   Hemophilia A
Intervention:   Drug: Recombinant Protein-Free Factor VIII (rAHF-PFM)
Sponsors:   Baxalta now part of Shire;   Baxalta Innovations GmbH, now part of Shire
Completed

Refine Your Search Advanced Search